Results 91 to 100 of about 1,168,324 (310)

Pharmacy Workload in Clinical Trial Management: A Preliminary Complexity Assessment Tool for Sponsored Oncology and Haematology Trials

Current Oncology
Investigational drug services need to be organised in a structured approach, especially for sites with a large number of ongoing clinical trials. The aim of this study was to develop a tool to assess the complexity of pharmacy involvement in a sponsored ...
Lorenzo Gasperoni, Carla Masini, Giada Toscano, Alessandro Cafaro, Chiara Zani, Cristina Andrianò, Paolo Silimbani, Caterina Donati, Giorgia Bortolin, Sara Cecco   +9 more
doaj   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Industry perspectives on market access of innovative drugs

Frontiers in Pharmacology, 2016
This study presents industry perspectives on the challenges related to market access of innovative drugs in general and oncology drugs in specific.
Kim ePauwels, Isabelle eHuys, Minne eCasteels, Steven eSimoens   +3 more
doaj   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Expression of Concern: Case report: A rare case of tumor-to-tumor metastasis: metastatic lobular breast carcinoma to clear cell renal cell carcinoma

Pathology and Oncology Research, 2023
Pathology & Oncology Research Editorial Office
doaj   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Mesenchymal hepatic hamartoma: A rare case of severe respiratory distress in a neonate

Clinical Case Reports
Key Clinical Message It is critical to consider intra‐abdominal pathology in cases of neonatal respiratory distress. Accurate and prompt diagnosis via computed tomography is lifesaving. We have highlighted the effectiveness of rapid surgical intervention
Kareem Omran, Jayasheela Kannan, Nisha Soares, Sameh Ali, Wissam Jamal Al Tamr   +4 more
doaj   +1 more source

Bioethical and Human Right Considerations during COVID-19 Pandemic Period: Reflections of Integrated Oncology Clinical Services from India

Indian Journal of Medical and Paediatric Oncology
Ever since the outbreak of COVID-19, the global health care systems are overwhelmed to cope up with the rapidly evolving disease paradigm through implementation of action plans at societal and medical domains.
Lal P. Madathil, Princy Louis Palatty, Dhanya Sacheendran, Mamatha Jayachander, Thomas George, Arpita Gur, Abhishek Krishna, Russell Franco D'souza, Manjeshwar Shrinath Baliga   +8 more
doaj   +1 more source

Report on hearing loss in oncology Classificações das perdas auditivas em Oncologia

Brazilian Journal of Otorhinolaryngology, 2009
Cisplatin is used frequently as an antineoplastic drug in the treatment of many different cancers. However, when used in doses over 360mg/m², ototoxicity may ensue, resulting in loss of hearing.
Christiane Schultz, Maria Valéria Schmidt Goffi-Gomez, Patrícia Helena Pecora Liberman, André Lopes Carvalho   +3 more
doaj   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source